Drug intelligence / Profile preview

CEN-209

Development stage: Unknown
Lead developer: Centella Therapeutics
Modality: Small Molecules

Overview

**CEN-209** (also known as SN30000) is a hypoxia-activated prodrug designed to selectively target and damage DNA in oxygen-starved (hypoxic) regions of solid tumors, which are resistant to standard radiotherapy and chemotherapy. Developed as an improved analog of tirapazamine with enhanced tumor penetration, it is bioreductively activated under low-oxygen conditions to generate cytotoxic metabolites, complementing radiation and chemotherapy by killing cells furthest from blood vessels. Discovered at the Auckland Cancer Society Research Centre by researchers including Professors William Wilson and Michael Hay, it was exclusively licensed to Centella Therapeutics (a Varian Medical Systems subsidiary) in 2011, with Cancer Research UK later partnering for preclinical development and Phase I trials via their Clinical Development Partnerships.[1][3][5]

Targets

DNA

Beyond the preview

Go deeper on CEN-209.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CEN-209.